Keymed Biosciences Inc. (2162.HK)

HKD 48.0

(7.5%)

Total Liabilities Summary of Keymed Biosciences Inc.

  • Keymed Biosciences Inc.'s latest annual total liabilities in 2023 was 896.1 Million CNY , up 51.09% from previous year.
  • Keymed Biosciences Inc.'s latest quarterly total liabilities in 2024 Q1 was 1.16 Billion CNY , up 30.37% from previous quarter.
  • Keymed Biosciences Inc. reported annual total liabilities of 593.09 Million CNY in 2022, up 105.17% from previous year.
  • Keymed Biosciences Inc. reported annual total liabilities of 289.07 Million CNY in 2021, down -82.21% from previous year.
  • Keymed Biosciences Inc. reported quarterly total liabilities of 1.16 Billion CNY for 2024 Q1, up 30.37% from previous quarter.
  • Keymed Biosciences Inc. reported quarterly total liabilities of 896.1 Million CNY for 2023 Q3, up 29.23% from previous quarter.

Annual Total Liabilities Chart of Keymed Biosciences Inc. (2023 - 2019)

Historical Annual Total Liabilities of Keymed Biosciences Inc. (2023 - 2019)

Year Total Liabilities Total Liabilities Growth
2023 896.1 Million CNY 51.09%
2022 593.09 Million CNY 105.17%
2021 289.07 Million CNY -82.21%
2020 1.62 Billion CNY 73.86%
2019 934.53 Million CNY 0.0%

Peer Total Liabilities Comparison of Keymed Biosciences Inc.

Name Total Liabilities Total Liabilities Difference
Uni-Bio Science Group Limited 152.81 Million HKD -486.39%
CK Life Sciences Int'l., (Holdings) Inc. 7.05 Billion HKD 87.304%